Center-Authored Papers

Filters: Author is Hirsch, Betsy A  [Clear All Filters]
G
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L et al..  2014.  Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Gudgeon CJ, Harrington KH, Laszlo GS, Alonzo TA, Gerbing RB, Gamis AS, Raimondi SC, Hirsch BA, Meshinchi S, Walter RB.  2013.  High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 54(1):202-204.
Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang Y-CJ, Kahwash SB, Heerema-McKenney A et al..  2017.  Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531.. Blood.
H
Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA et al..  2011.  Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.. Blood. 118(17):4561-6. Abstract
K
Kutny MA, Alonzo TA, Gerbing RB, Wang Y-C, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH et al..  2017.  Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016716183. Abstract
L
Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang Y-C, Ries RE, Aplenc R, Hirsch BA, Raimondi SC et al..  2017.  CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016712513. Abstract
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2015.  High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 8(1):115. Abstract
Laszlo G, Alonzo TA, Gudgeon C, Harrington K, Gerbing R, Wang Y-C, Ries R, Raimondi S, Hirsch BA, Gamis A et al..  2015.  Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. 21(14):3187-95. Abstract
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang Y-C, Ries RE, Raimondi SC, Hirsch BA et al..  2016.  Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Journal of hematology & oncology. 9(1):133.
Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S et al..  2014.  High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.. Leukemia & lymphoma. 55(12):2817-21. Abstract
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS et al..  2012.  Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.. Blood. Abstract
M
Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S.  2013.  BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
O
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR et al..  2014.  NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.. Blood. 124(15):2400-7. Abstract
P
Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.  2016.  CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
R
Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang Y-C, Loken MR, Raimondi SC, Hirsch BA, Gamis AS et al..  2016.  miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.. Pediatric blood & cancer. Abstract
T
Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS et al..  2014.  Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.. British journal of haematology. Abstract
Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi S, Hirsch BA, Kahwash SB et al..  2017.  Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Tarlock K, Alonzo TA, Gerbing R, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis A et al..  2015.  Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
W
Walter RB, Alonzo TA, Gerbing RB, Ho PA, Smith FO, Raimondi SC, Hirsch BA, Gamis AS, Franklin JL, Hurwitz CA et al..  2010.  High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17):2831-8. Abstract
Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC et al..  2013.  Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: A report from the children's oncology group.. American journal of hematology. 88(8):694-702. Abstract